Clinical trials
for patients
Learn about available clinical trials
-
December 30, 2024PamplonaIn recruitment
KT-US-679-0788 The purpose of this study is to find out whether the experimental treatment, anito-cel, is safe and effective for the treatment of their relapsed or refractory multiple myeloma compared to the reference treatment.
The purpose of this study is to find out whether the experimental treatment, anito-cel, is safe and effective for the treatment of their relapsed or refractory multiple myeloma compared to the reference treatment. -
December 30, 2024PamplonaIn recruitmentEarly phase
KQB198-101 Phase 1/1b, open-label, multicenter, stepwise escalation and dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of KQB198 in monotherapy and in combination with antineoplastics in participants with advanced solid malignancies
The aim is to test an investigational (experimental) drug called KQB198 that could help stop the growth of cancer cells. -
December 30, 2024Pamplona/MadridIn recruitmentEarly phase
LCB-2401-001 Phase 1, open-label, dose-finding clinical trial of nilk-2401, a bispecific, ceacam5 x cd47 Antibody, as a single agent and in combination with anti-pd-1 Antibody, in patients with ceacam5-expressing solid cancers.
The aim of this research is to evaluate whether NILK-2401 as a single agent has beneficial effects and is safe in patients with these cancers. -
December 19, 2024Pamplona/MadridIn recruitment
IMC-F106C-301 Trial of BMI-F106C plus nivolumab vs. nivolumab in HLA A*02:01-positive participants with previously untreated advanced melanoma.
The main objective of this study is to know whether the study drug (IMC-F106C at two different doses) in combination with the reference treatment (nivolumab) is better than nivolumab alone in keeping tumors from increasing or decreasing in size. -
December 16, 2024PamplonaIn recruitment
CCTL019A2205B Long-term follow-up of patients exposed to lentiviral vector-based CART cell therapy.
This is a long-term follow-up trial sponsored (funded) by the pharmaceutical company Novartis. If you agree to participate in this study, you will be followed for up to 15 years after your last infusion of your CART cells to assess both the safety and risk of late safety problems suspected to be related to the treatment of your CART cells, or certain laboratory parameters, and efficacy including the status of your primary malignancy. -
December 16, 2024Pamplona/MadridIn recruitment
EIK1003-001 Phase I/II clinical trial of the selective PARP1 inhibitor, IMP1734, in participants with advanced solid tumors.
The main objective of this study is to evaluate the extent to which IMP1734 is tolerated, alone and in combination with other anticancer drugs, as a treatment for patients with ovarian, breast, prostate and pancreatic cancer. -
December 11, 2024MadridIn recruitment
-
December 11, 2024Pamplona/MadridIn recruitmentEarly phase
CA119-0002 Ensayo Clínico de BMS-986453, linfocitos T con receptor antigénico quimérico (CAR) con diana doble de BCMAxGPRC5D en sujetos con mieloma múltiple en recaída o refractario
The objective of this study is to assess whether BMS-986453 is safe and effective for treating people whose multiple myeloma (MM) has recurred after previous treatment (relapsed) or who have MM that is not responding to current treatment (refractory). -
December 11, 2024Pamplona/MadridIn recruitment
SPI-BEL-301 Trial of Beleodaq-CHOP or Folotyn-COP with the CHOP dosing regimen in monotherapy in patients with newly diagnosed peripheral T lymphocyte lymphoma.
Part 1 of this study is mainly aimed at finding out what is the best dose of belinostat and pralatrexate together for administration together with another drug combination in Part 2 of the study. The main objective of Part 2 of the study is to evaluate the safety and efficacy of belinostat together with CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], oncovin [vincristine] and prednisone), and the safety and efficacy of pralatrexate together with COP (CHOP without hydroxydaunorubicin [... -
December 11, 2024Pamplona/MadridIn recruitment
ART0380C001 Trial of ART0380 as oral and gemcitabine treatment in patients with advanced or metastatic solid tumor.
The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be administered along with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be administered to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can th...